Oct 29, 2024 / NTS GMT
Operator
Ladies and gentlemen, good day and welcome to the Glaxo Smith Kline Pharmaceuticals Limited Q2 earnings analyst conference call. (Operator Instructions). I now hand the conference over to Mr. Bhushan Akshikar. Thank you and over to you, sir.
Bhushan Akshikar - GlaxoSmithKline Pharmaceuticals Ltd - Managing Director, Executive Director
Thank you very much for setting this up. A very, very good afternoon to everybody on the call in the next 20 minutes or so. I and the UVR CFO will take us through the results for Q2 of 2024. And before we dive deep, dive into the financials, I want to begin by wishing everyone a very happy hunter just at the cusp of celebrating Diwali. So wish you the very best and a very prosperous Diwali to all of us. Can we move to the next slide?
So we just concluded our board meeting this afternoon and before we go and look at the specifics on the financials, just want to contextualize our performance, our competitive performance. As we see it reflected in the external data sources. As each one of you is aware, we continue to be a broadly
Q2 2025 GlaxoSmithKline Pharmaceuticals Ltd Earnings Call Transcript
Oct 29, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers